Global Drugs for Duchenne Muscular Dystrophy (DMD) Market 2021 by Company, Regions, Type and Application, Forecast to 2026
The Drugs for Duchenne Muscular Dystrophy (DMD) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Drugs for Duchenne Muscular Dystrophy (DMD) size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Drugs for Duchenne Muscular Dystrophy (DMD) market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Drugs for Duchenne Muscular Dystrophy (DMD) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Eteplirsen
Deflazacort
Ataluren
Market segment by Application, can be divided into
Hospitals
Clinics
Home Care
Market segment by players, this report covers
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
WaVe life Science
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Drugs for Duchenne Muscular Dystrophy (DMD)
1.2 Classification of Drugs for Duchenne Muscular Dystrophy (DMD) by Type
1.2.1 Overview: Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type in 2020
1.2.3 Eteplirsen
1.2.4 Deflazacort
1.2.5 Ataluren
1.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market by Application
1.3.1 Overview: Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size & Forecast
1.5 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast by Region
1.5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region, (2016-2021)
1.5.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Prospect (2016-2026)
1.5.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Prospect (2016-2026)
1.5.6 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers
1.6.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints
1.6.3 Drugs for Duchenne Muscular Dystrophy (DMD) Trends Analysis
2 Company Profiles
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business
2.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
2.1.4 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
2.2 PTC Therapeutics
2.2.1 PTC Therapeutics Details
2.2.2 PTC Therapeutics Major Business
2.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
2.2.4 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 PTC Therapeutics Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
2.3.4 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
2.4.4 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 Italfarmaco
2.5.1 Italfarmaco Details
2.5.2 Italfarmaco Major Business
2.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
2.5.4 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Italfarmaco Recent Developments and Future Plans
2.6 Santhera Pharmaceuticals
2.6.1 Santhera Pharmaceuticals Details
2.6.2 Santhera Pharmaceuticals Major Business
2.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
2.6.4 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Santhera Pharmaceuticals Recent Developments and Future Plans
2.7 WaVe life Science
2.7.1 WaVe life Science Details
2.7.2 WaVe life Science Major Business
2.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
2.7.4 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 WaVe life Science Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share
3.2.2 Top 10 Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share
3.2.3 Market Competition Trend
3.3 Drugs for Duchenne Muscular Dystrophy (DMD) Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Market Share by Type (2016-2021)
4.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2016-2021)
5.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2026)
6.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2026)
6.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
6.3.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2016-2026)
6.3.2 United States Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
6.3.3 Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
6.3.4 Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2026)
7.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2026)
7.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
7.3.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2016-2026)
7.3.2 Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
7.3.3 France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
7.3.5 Russia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
7.3.6 Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2026)
8.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2026)
8.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.3.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Region (2016-2026)
8.3.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
8.3.3 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
8.3.4 South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
8.3.5 India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
8.3.7 Australia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2026)
9.2 South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2026)
9.3 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
9.3.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2016-2026)
9.3.2 Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
9.3.3 Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2026)
10.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2026)
10.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
10.3.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2016-2026)
10.3.2 Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
10.3.4 UAE Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million) by Region (2016-2021)
Table 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2021-2026)
Table 6. Sarepta Therapeutics Corporate Information, Head Office, and Major Competitors
Table 7. Sarepta Therapeutics Major Business
Table 8. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
Table 9. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. PTC Therapeutics Corporate Information, Head Office, and Major Competitors
Table 11. PTC Therapeutics Major Business
Table 12. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
Table 13. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Pfizer Corporate Information, Head Office, and Major Competitors
Table 15. Pfizer Major Business
Table 16. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
Table 17. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 19. Bristol-Myers Squibb Major Business
Table 20. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
Table 21. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Italfarmaco Corporate Information, Head Office, and Major Competitors
Table 23. Italfarmaco Major Business
Table 24. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
Table 25. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Santhera Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Santhera Pharmaceuticals Major Business
Table 28. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
Table 29. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. WaVe life Science Corporate Information, Head Office, and Major Competitors
Table 31. WaVe life Science Major Business
Table 32. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product and Solutions
Table 33. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million) by Players (2019-2021)
Table 35. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Players (2019-2021)
Table 36. Breakdown of Drugs for Duchenne Muscular Dystrophy (DMD) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 37. Drugs for Duchenne Muscular Dystrophy (DMD) Players Head Office, Products and Services Provided
Table 38. Drugs for Duchenne Muscular Dystrophy (DMD) Mergers & Acquisitions in the Past Five Years
Table 39. Drugs for Duchenne Muscular Dystrophy (DMD) New Entrants and Expansion Plans
Table 40. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million) by Type (2016-2021)
Table 41. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2016-2021)
Table 42. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Forecast by Type (2021-2026)
Table 43. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2021)
Table 44. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Forecast by Application (2021-2026)
Table 45. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2021) & (USD Million)
Table 46. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (USD Million)
Table 47. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2021) & (USD Million)
Table 48. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (USD Million)
Table 49. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2016-2021) & (USD Million)
Table 50. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026) & (USD Million)
Table 51. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2021) & (USD Million)
Table 52. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (USD Million)
Table 53. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2021) & (USD Million)
Table 54. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (USD Million)
Table 55. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2016-2021) & (USD Million)
Table 56. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026) & (USD Million)
Table 57. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2021) & (USD Million)
Table 58. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (USD Million)
Table 59. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2021) & (USD Million)
Table 60. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (USD Million)
Table 61. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Region (2016-2021) & (USD Million)
Table 62. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Region (2021-2026) & (USD Million)
Table 63. South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2021) & (USD Million)
Table 64. South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (USD Million)
Table 65. South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2021) & (USD Million)
Table 66. South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (USD Million)
Table 67. South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2016-2021) & (USD Million)
Table 68. South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026) & (USD Million)
Table 69. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2016-2021) & (USD Million)
Table 70. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (USD Million)
Table 71. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2016-2021) & (USD Million)
Table 72. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (USD Million)
Table 73. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2016-2021) & (USD Million)
Table 74. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Drugs for Duchenne Muscular Dystrophy (DMD) Picture
Figure 2. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type in 2020
Figure 3. Eteplirsen
Figure 4. Deflazacort
Figure 5. Ataluren
Figure 6. Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application in 2020
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Home Care Picture
Figure 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2016-2026)
Figure 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region in 2020
Figure 14. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers
Figure 20. Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints
Figure 21. Drugs for Duchenne Muscular Dystrophy (DMD) Market Trends
Figure 22. Sarepta Therapeutics Recent Developments and Future Plans
Figure 23. PTC Therapeutics Recent Developments and Future Plans
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 26. Italfarmaco Recent Developments and Future Plans
Figure 27. Santhera Pharmaceuticals Recent Developments and Future Plans
Figure 28. WaVe life Science Recent Developments and Future Plans
Figure 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Players in 2020
Figure 30. Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 31. Global Top 3 Players Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share in 2020
Figure 32. Global Top 10 Players Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share in 2020
Figure 33. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type in 2020
Figure 35. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Type (2021-2026)
Figure 36. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application in 2020
Figure 37. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Application (2021-2026)
Figure 38. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2016-2026)
Figure 39. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2016-2026)
Figure 40. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Country (2016-2026)
Figure 41. United States Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2016-2026)
Figure 45. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2016-2026)
Figure 46. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Country (2016-2026)
Figure 47. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. France Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. United Kingdom Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2016-2026)
Figure 53. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2016-2026)
Figure 54. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2016-2026)
Figure 55. China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. India Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2016-2026)
Figure 62. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2016-2026)
Figure 63. South America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Country (2016-2026)
Figure 64. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2016-2026)
Figure 67. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2016-2026)
Figure 68. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Country (2016-2026)
Figure 69. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Methodology
Figure 73. Research Process and Data Source
